Click here for links to all Expanded Tables of Contents EXPANDED TABLE OF CONTENTS VOLUME 11, NUMBER 3    MARCH 2008 TREATMENT HIGHLIGHTS QUALITY OF SLEEP AND THE RISK FOR DEVELOPING DIABETES Decreased duration of slow-wave sleep may increase the risk for developing diabetes. PREDICTION OF PSYCHOSIS Among patients at high risk for developing psychosis, several factors are found to predict an increased risk for developing psychosis. TODDLERS’ EXPOSURE TO VIOLENT TELEVISION PROGRAMS Among boys, exposure to violent television programs at ages 2 through 4 is associated with an increased risk for subsequent antisocial behavior in childhood. QUICKSTATS Hypertension Treatment for Depression in Adults PSYCHOPHARMACOLOGY NOTE PLACEBO EFFECT AND THE IMPACT OF ANTIDEPRESSANT TREATMENT A research review of FDA clinical trial data does not find clinically significant differences between response to antidepressant medication and to placebo, except in cases of very severe depression. FDA NEWS AND REVIEW Approval: Kuvan (sapropterin dihydrochloride) is approved for treatment of phenylketonuria. Approval: Pristiq (desvenlafaxine succinate) is approved for treatment of major depressive disorder. Product Safety Information: Tamiflu (oseltamivir phosphate) is the subject of postmarketing reports of serious, sometimes fatal, neuropsychiatric events. ASSESSMENT Mental Health Screening Form-III (MHSF-III) RESOURCES Each issue presents descriptions of clinical resources (eg, professional materials, patient handouts) and information on how to receive those materials.